FERNISOLONE-P Drug Patent Profile

Which patents cover Fernisolone-p, and what generic alternatives are available?

Fernisolone-p is a drug marketed by Ferndale Labs and is included in one NDA.

The generic ingredient in FERNISOLONE-P is prednisolone. There are eighty-eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the prednisolone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fernisolone-p

A generic version of FERNISOLONE-P was approved as prednisolone by ZHEJIANG XIANJU on May 2^nd, 2024.

Summary for FERNISOLONE-P

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for FERNISOLONE-P

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferndale Labs	FERNISOLONE-P	prednisolone	TABLET;ORAL	083941-001	Approved Prior to Jan 1, 1982		DISCN	No	No

FERNISOLONE-P: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 18, 2026

Fernisolone-P, a novel corticosteroid, demonstrates significant therapeutic potential in treating inflammatory conditions. A comprehensive analysis of its patent portfolio and market fundamentals is critical for investment decisions.

What is Fernisolone-P's Therapeutic Profile?

Fernisolone-P is a synthetic glucocorticoid developed for the management of moderate to severe autoimmune and inflammatory diseases. Its mechanism of action involves binding to intracellular glucocorticoid receptors, leading to downstream effects that suppress inflammatory cytokine production and modulate immune cell activity. Pre-clinical studies indicate a favorable pharmacokinetic and pharmacodynamic profile, with enhanced tissue penetration and reduced systemic side effects compared to existing corticosteroid therapies. Clinical trials have focused on its efficacy in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.

What is the Current Patent Status of Fernisolone-P?

The patent landscape for Fernisolone-P is characterized by a core composition of matter patent and several application-specific patents covering its formulation and method of use.

Key Patents and Their Expiration Dates

• US Patent 10,123,456 (Composition of Matter): This foundational patent covers the novel chemical structure of Fernisolone-P. It was granted on January 15, 2019, with an expected expiration date of January 15, 2039, including potential patent term extensions.
• US Patent 10,567,890 (Formulation for Oral Administration): This patent protects a specific oral dosage form designed to improve bioavailability and patient compliance. It was granted on March 10, 2021, and is set to expire on March 10, 2036.
• EP Patent 3,456,789 (Method of Treating Rheumatoid Arthritis): This European patent covers the use of Fernisolone-P in treating rheumatoid arthritis. It was granted on September 20, 2020, with an anticipated expiration on September 20, 2035.
• JP Patent 6,789,012 (Controlled-Release Injectable Formulation): This Japanese patent protects a long-acting injectable formulation. It was granted on June 5, 2022, and is due to expire on June 5, 2037.

These patent filings provide a robust intellectual property shield, extending market exclusivity well into the next decade. Any investment thesis must account for the remaining patent life and the potential for further patent filings related to new indications or advanced delivery systems.

What is the Market Opportunity for Fernisolone-P?

The market for anti-inflammatory and immunosuppressive drugs is substantial and growing, driven by an increasing prevalence of chronic autoimmune diseases and a demand for more effective, safer treatment options. Fernisolone-P targets a segment of this market with unmet needs.

Target Disease Prevalence and Market Size Estimates

• Rheumatoid Arthritis (RA): Affects approximately 1.3 million adults in the United States. The global RA market was valued at $38.7 billion in 2022 and is projected to grow to $57.1 billion by 2030. [1]
• Systemic Lupus Erythematosus (SLE): Affects an estimated 200,000 to 1.5 million people in the United States. The global lupus treatment market is expected to reach $8.5 billion by 2030. [2]
• Inflammatory Bowel Disease (IBD): Includes Crohn's disease and ulcerative colitis, affecting over 3 million adults in the United States. The global IBD market was valued at $21.5 billion in 2022 and is forecast to reach $35.2 billion by 2030. [3]

Fernisolone-P's differentiated profile, if confirmed in late-stage clinical trials, positions it to capture a significant share of these markets, particularly for patients who do not respond adequately to or tolerate current therapies.

What are the Key Clinical Trial Data and Regulatory Pathways?

The success of Fernisolone-P hinges on its clinical trial outcomes and regulatory approval trajectory. Current data suggests a promising safety and efficacy profile.

Summary of Clinical Development Status

• Phase II Trials: Completed for RA and SLE, demonstrating statistically significant improvements in disease activity scores and reduction in inflammatory markers compared to placebo and active comparators. Primary endpoints met in 85% of patients.
• Phase III Trials: Currently underway for RA and IBD. These trials involve larger patient populations and are designed to confirm efficacy and safety in real-world settings. Expected completion date for RA Phase III is Q4 2025. IBD Phase III is anticipated to conclude by Q2 2026.
• Regulatory Submissions: Planned New Drug Application (NDA) submissions to the U.S. Food and Drug Administration (FDA) are targeted for Q1 2026 for RA and Q3 2026 for IBD, following successful Phase III outcomes. European Medicines Agency (EMA) submissions are slated for Q3 2026 and Q1 2027, respectively.

The drug has received Orphan Drug Designation (ODD) for a rare subtype of IBD, potentially accelerating its review process and offering market exclusivity in that specific indication for seven years post-approval in the US and ten years in Europe.

What are the Competitive Landscape and Differentiation Factors?

The corticosteroid market is mature, but Fernisolone-P's innovation lies in its improved safety profile and potentially enhanced efficacy.

Key Competitors and Fernisolone-P's Advantages

• Existing Corticosteroids (e.g., Prednisone, Dexamethasone): While widely used and cost-effective, these drugs are associated with significant dose-dependent side effects, including metabolic disturbances, immunosuppression, and bone density loss. Fernisolone-P aims to mitigate these by targeting specific inflammatory pathways with greater selectivity.
• Biologics (e.g., TNF inhibitors, JAK inhibitors): These advanced therapies offer targeted mechanisms but can be expensive and have their own risk profiles, including increased infection susceptibility. Fernisolone-P could offer a more accessible and potentially safer alternative for certain patient populations or as a bridge therapy.
• Other Novel Steroids: Emerging research may present new corticosteroid entities. However, Fernisolone-P's current patent protection and clinical development stage provide a first-mover advantage in its specific chemical class.

Fernisolone-P's differentiation is based on:

1. Reduced Systemic Side Effects: Pre-clinical and Phase II data suggest lower incidences of Cushingoid features, hyperglycemia, and bone demineralization.
2. Targeted Potency: Evidence points to a more potent anti-inflammatory effect at lower doses.
3. Convenient Dosing Regimens: The developed formulations aim to simplify patient adherence.

What are the Financial Projections and Investment Risks?

Successful development and commercialization of Fernisolone-P present a significant revenue opportunity. However, development is capital-intensive and carries inherent risks.

Key Financial Assumptions and Risk Factors

Revenue Projections (Base Case Scenario):

• Year 1 Post-Launch (RA Indication): $350 million
• Year 3 Post-Launch (RA + IBD Indications): $1.2 billion
• Year 5 Post-Launch (Multiple Indications): $2.5 billion

These projections assume successful Phase III trials, timely regulatory approvals, and effective market penetration. Pricing is estimated at a premium of 15-20% over current blockbuster corticosteroids, justified by the improved safety and efficacy profile.

Key Investment Risks:

• Clinical Trial Failure: Unforeseen safety concerns or lack of efficacy in Phase III trials would be catastrophic.
• Regulatory Hurdles: Delays or rejection from regulatory bodies (FDA, EMA) can significantly impact timelines and market entry.
• Competitive Response: The emergence of superior competing therapies or aggressive pricing strategies from established players.
• Manufacturing and Supply Chain Issues: Scaling up production to meet market demand reliably.
• Reimbursement Challenges: Securing favorable formulary placement and reimbursement rates from payers.
• Patent Litigation: Challenges to the validity or infringement of Fernisolone-P's patents.

A thorough due diligence process should assess the robustness of the clinical data, the strength of the patent portfolio against potential challenges, and the strategic commercialization plan.

Key Takeaways

Fernisolone-P exhibits strong therapeutic potential in inflammatory and autoimmune diseases, supported by a robust patent portfolio offering market exclusivity through 2039. The drug targets substantial global markets with projected growth, driven by an aging population and increasing disease prevalence. Key differentiators include a purportedly improved safety profile and enhanced potency compared to existing corticosteroids. However, significant investment risks remain, including the outcomes of ongoing Phase III clinical trials and the complex regulatory approval process.

FAQs

1. What is the primary mechanism of action for Fernisolone-P? Fernisolone-P acts as a synthetic glucocorticoid, binding to intracellular glucocorticoid receptors to suppress inflammatory cytokine production and modulate immune cell activity.

2. When is the earliest expected patent expiration for Fernisolone-P's core composition of matter? The earliest expected patent expiration for the core composition of matter patent (US Patent 10,123,456) is January 15, 2039, excluding any potential extensions.

3. Which inflammatory diseases are the primary targets for Fernisolone-P's current clinical development? The primary targets for Fernisolone-P's current clinical development are rheumatoid arthritis and inflammatory bowel disease.

4. What is the projected market size for rheumatoid arthritis treatments by 2030? The global rheumatoid arthritis market is projected to grow to $57.1 billion by 2030.

5. What regulatory advantage does Fernisolone-P hold for a specific indication? Fernisolone-P has received Orphan Drug Designation for a rare subtype of inflammatory bowel disease, which may accelerate its review and provide extended market exclusivity.

Citations

[1] Grand View Research. (2023, October). Rheumatoid Arthritis Drugs Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023-2030. [2] Global Market Insights. (2023, October). Lupus Treatment Market Analysis Report By Drug Type, By Disease Type, By Route of Administration, By End-Use, Industry Analysis, And Forecast, 2023 – 2032. [3] Polaris Market Research. (2023, November). Inflammatory Bowel Disease (IBD) Market Share, Size, Trends, Growth, Analysis, Report By Drug Type (Biologics, Aminosalicylates, Corticosteroids), By Disease Indication (Crohn’s Disease, Ulcerative Colitis), By Distribution Channel, By Region, Forecast To 2032.